Cash from Investing (TTM) Chart

View Cash from Investing (TTM) for NKTR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (TTM) Chart
Start Trial

Historical Cash from Investing (TTM) Data

View and export this data back to 1998. Start Trial.
Date Value
March 31, 2026 -395.68M
December 31, 2025 -1.197M
September 30, 2025 58.64M
June 30, 2025 199.63M
March 31, 2025 167.00M
December 31, 2024 142.57M
September 30, 2024 99.74M
June 30, 2024 110.04M
March 31, 2024 118.22M
December 31, 2023 139.56M
September 30, 2023 162.20M
June 30, 2023 217.18M
March 31, 2023 276.16M
December 31, 2022 365.84M
September 30, 2022 446.02M
June 30, 2022 333.79M
March 31, 2022 322.60M
December 31, 2021 202.78M
September 30, 2021 175.32M
June 30, 2021 224.82M
March 31, 2021 308.90M
December 31, 2020 496.21M
September 30, 2020 538.95M
June 30, 2020 548.54M
March 31, 2020 416.79M
Date Value
December 31, 2019 206.89M
September 30, 2019 158.94M
June 30, 2019 -520.58M
March 31, 2019 -1.440B
December 31, 2018 -1.380B
September 30, 2018 -1.444B
June 30, 2018 -903.92M
March 31, 2018 32.47M
December 31, 2017 -28.81M
September 30, 2017 -193.89M
June 30, 2017 -84.82M
March 31, 2017 -131.72M
December 31, 2016 -82.40M
September 30, 2016 52.50M
June 30, 2016 4.823M
March 31, 2016 -56.25M
December 31, 2015 -39.34M
September 30, 2015 -56.94M
June 30, 2015 2.504M
March 31, 2015 73.80M
December 31, 2014 -37.57M
September 30, 2014 -94.91M
June 30, 2014 -93.28M
March 31, 2014 -51.99M
December 31, 2013 49.91M

Cash From Investing Definition

Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.

Read full definition.

Cash from Investing (TTM) Range, Past 5 Years

View Cash from Investing (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (TTM) Benchmarks

View Cash from Investing (TTM) Benchmarks
Start Trial
Aquestive Therapeutics, Inc. -0.479M
Eli Lilly & Co. -11.54B
Boston Scientific Corp. -2.731B
Tvardi Therapeutics, Inc. -5.108M
Johnson & Johnson -24.33B